{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:37:28Z","timestamp":1770277048029,"version":"3.49.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T00:00:00Z","timestamp":1490313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T00:00:00Z","timestamp":1490313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Transplant-eligible patients with multiple myeloma (MM) now have extended survival after diagnosis owing to effective modern treatment strategies that include new agents in induction therapy, autologous stem cell transplant (ASCT), consolidation therapy and posttransplant maintenance therapy. Standard of care for newly diagnosed, fit patients includes ASCT and, often nowadays, posttransplant maintenance. Several large studies have shown the efficacy of maintenance with thalidomide, lenalidomide and bortezomib in the treatment scheme of MM with regards to prolonging progression-free survival and, to a lesser degree, overall survival. Herein we discuss the data currently available to support the use of maintenance therapy in patients after ASCT as well as the newer available agents that may be a part of its changing landscape in the years to come.<\/jats:p>","DOI":"10.1038\/bcj.2017.23","type":"journal-article","created":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T14:20:45Z","timestamp":1490365245000},"page":"e545-e545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Posttransplant maintenance therapy in multiple myeloma: the changing landscape"],"prefix":"10.1038","volume":"7","author":[{"given":"S","family":"Sengsayadeth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Malard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B N","family":"Savani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Garderet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,24]]},"reference":[{"key":"BFbcj201723_CR1","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516\u20132520.","journal-title":"Blood"},{"key":"BFbcj201723_CR2","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.2009.25.6081","volume":"28","author":"B Barlogie","year":"2010","unstructured":"Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol 2010; 28: 1209\u20131214.","journal-title":"J Clin Oncol"},{"key":"BFbcj201723_CR3","first-page":"8001","volume":"34","author":"M Attal","year":"2016","unstructured":"Attal M, Palumbo A, Holstein SA, Lauwers-Cances V, Petrucci MT, Richardson PG et al. Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): a meta-analysis (MA) of overall survival (OS). ASCO Meeting Abstr 2016; 34: 8001.","journal-title":"ASCO Meeting Abstr"},{"key":"BFbcj201723_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1365-2141.2006.06271.x","volume":"135","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158\u2013164.","journal-title":"Br J Haematol"},{"key":"BFbcj201723_CR5","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875\u20131883.","journal-title":"N Engl J Med"},{"key":"BFbcj201723_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91\u201397.","journal-title":"N Engl J Med"},{"key":"BFbcj201723_CR7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V126.23.391.391","volume":"126","author":"M Attal","year":"2015","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Facon T, Caillot D, Escoffre M et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM\/DFCI 2009 trial). Blood 2015; 126: 391\u2013391.","journal-title":"Blood"},{"key":"BFbcj201723_CR8","first-page":"8000","volume":"34","author":"M Cavo","year":"2016","unstructured":"Cavo M, Palumbo A, Zweegman S, Dimopoulos MA, Hajek R, Pantani L et al. Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02\/HO95 MM trial). ASCO Meeting Abstr 2016; 34: 8000.","journal-title":"ASCO Meeting Abstr"},{"key":"BFbcj201723_CR9","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/bmt.2015.83","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty M, Richardson PG, McCarthy PL, Attal M . Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand? Bone Marrow Transplant 2015; 50: 1024\u20131029.","journal-title":"Bone Marrow Transplant"},{"key":"BFbcj201723_CR10","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1200\/JCO.2013.49.0086","volume":"31","author":"P Kapoor","year":"2013","unstructured":"Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol 2013; 31: 4529\u20134535.","journal-title":"J Clin Oncol"},{"key":"BFbcj201723_CR11","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","volume":"31","author":"AC Rawstron","year":"2013","unstructured":"Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013; 31: 2540\u20132547.","journal-title":"J Clin Oncol"},{"key":"BFbcj201723_CR12","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.3324\/haematol.2015.128215","volume":"101","author":"RM de Tute","year":"2016","unstructured":"de Tute RM, Rawstron AC, Gregory WM, Child JA, Davies FE, Bell SE et al. Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen. Haematologica 2016; 101: e69\u2013e71.","journal-title":"Haematologica"},{"key":"BFbcj201723_CR13","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","volume":"123","author":"J Martinez-Lopez","year":"2014","unstructured":"Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014; 123: 3073\u20133079.","journal-title":"Blood"},{"key":"BFbcj201723_CR14","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","volume":"125","author":"AC Rawstron","year":"2015","unstructured":"Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood 2015; 125: 1932\u20131935.","journal-title":"Blood"},{"key":"BFbcj201723_CR15","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","volume":"113","author":"Myeloma Trialists\u2019 Collaborative Group","year":"2001","unstructured":"Myeloma Trialists\u2019 Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113: 1020\u20131034.","journal-title":"Br J Haematol"},{"key":"BFbcj201723_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/1096-8652(200011)65:3<204::AID-AJH5>3.0.CO;2-H","volume":"65","author":"R Alexanian","year":"2000","unstructured":"Alexanian R, Weber D, Dimopoulos M, Delasalle K, Smith TL . Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma. Am J Hematol 2000; 65: 204\u2013209.","journal-title":"Am J Hematol"},{"key":"BFbcj201723_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/bjc.1988.17","volume":"57","author":"A Belch","year":"1988","unstructured":"Belch A, Shelley W, Bergsagel D, Wilson K, Klimo P, White D et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988; 57: 94\u201399.","journal-title":"Br J Cancer"},{"key":"BFbcj201723_CR18","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","volume":"99","author":"JR Berenson","year":"2002","unstructured":"Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99: 3163\u20133168.","journal-title":"Blood"},{"key":"BFbcj201723_CR19","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1023\/A:1026548226770","volume":"11","author":"E Fritz","year":"2000","unstructured":"Fritz E, Ludwig H . Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 2000; 11: 1427\u20131436.","journal-title":"Ann Oncol"},{"key":"BFbcj201723_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1365-2141.2006.06405.x","volume":"136","author":"C Shustik","year":"2007","unstructured":"Shustik C, Belch A, Robinson S, Rubin SH, Dolan SP, Kovacs MJ et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol 2007; 136: 203\u2013211.","journal-title":"Br J Haematol"},{"key":"BFbcj201723_CR21","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565\u20131571.","journal-title":"N Engl J Med"},{"key":"BFbcj201723_CR22","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","volume":"20","author":"SV Rajkumar","year":"2002","unstructured":"Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319\u20134323.","journal-title":"J Clin Oncol"},{"key":"BFbcj201723_CR23","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"M Cavo","year":"2010","unstructured":"Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075\u20132085.","journal-title":"Lancet"},{"key":"BFbcj201723_CR24","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","volume":"108","author":"M Attal","year":"2006","unstructured":"Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289\u20133294.","journal-title":"Blood"},{"key":"BFbcj201723_CR25","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJMoa053583","volume":"354","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021\u20131030.","journal-title":"N Engl J Med"},{"key":"BFbcj201723_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","volume":"119","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012; 119: 7\u201315.","journal-title":"Blood"},{"key":"BFbcj201723_CR27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","volume":"115","author":"HM Lokhorst","year":"2010","unstructured":"Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010; 115: 1113\u20131120.","journal-title":"Blood"},{"key":"BFbcj201723_CR28","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","volume":"121","author":"AK Stewart","year":"2013","unstructured":"Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood 2013; 121: 1517\u20131523.","journal-title":"Blood"},{"key":"BFbcj201723_CR29","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/ajh.23274","volume":"87","author":"A Maiolino","year":"2012","unstructured":"Maiolino A, Hungria VT, Garnica M, Oliveira-Duarte G, Oliveira LC, Mercante DR et al. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. Am J Hematol 2012; 87: 948\u2013952.","journal-title":"Am J Hematol"},{"key":"BFbcj201723_CR30","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.leukres.2012.04.001","volume":"36","author":"Y Kagoya","year":"2012","unstructured":"Kagoya Y, Nannya Y, Kurokawa M . Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. Leuk Res 2012; 36: 1016\u20131021.","journal-title":"Leuk Res"},{"key":"BFbcj201723_CR31","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","volume":"22","author":"SA Schey","year":"2004","unstructured":"Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22: 3269\u20133276.","journal-title":"J Clin Oncol"},{"key":"BFbcj201723_CR32","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B et al. Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050\u20134053.","journal-title":"Blood"},{"key":"BFbcj201723_CR33","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123\u20132132.","journal-title":"N Engl J Med"},{"key":"BFbcj201723_CR34","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133\u20132142.","journal-title":"N Engl J Med"},{"key":"BFbcj201723_CR35","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782\u20131791.","journal-title":"N Engl J Med"},{"key":"BFbcj201723_CR36","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770\u20131781.","journal-title":"N Engl J Med"},{"key":"BFbcj201723_CR37","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371: 895\u2013905.","journal-title":"N Engl J Med"},{"key":"BFbcj201723_CR38","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","volume":"16","author":"F Gay","year":"2015","unstructured":"Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol 2015; 16: 1617\u20131629.","journal-title":"Lancet Oncol"},{"key":"BFbcj201723_CR39","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","volume":"20","author":"RZ Orlowski","year":"2002","unstructured":"Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420\u20134427.","journal-title":"J Clin Oncol"},{"key":"BFbcj201723_CR40","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","volume":"28","author":"JL Harousseau","year":"2010","unstructured":"Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28: 4621\u20134629.","journal-title":"J Clin Oncol"},{"key":"BFbcj201723_CR41","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J Clin Oncol 2012; 30: 2946\u20132955.","journal-title":"J Clin Oncol"},{"key":"BFbcj201723_CR42","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","volume":"118","author":"P Moreau","year":"2011","unstructured":"Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011; 118: 5752\u20135758, quiz 5982.","journal-title":"Blood"},{"key":"BFbcj201723_CR43","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","volume":"120","author":"L Rosinol","year":"2012","unstructured":"Rosinol L, Oriol A, Teruel AI, Hernandez D, Lopez-Jimenez J, de la Rubia J et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study. Blood 2012; 120: 1589\u20131596.","journal-title":"Blood"},{"key":"BFbcj201723_CR44","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487\u20132498.","journal-title":"N Engl J Med"},{"key":"BFbcj201723_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1182\/blood-2015-05-643338","volume":"126","author":"P Sonneveld","year":"2015","unstructured":"Sonneveld P, Salwender H-J, Van Der Holt B, el Jarari L, Bertsch U, Blau IW et al. Bortezomib induction and maintenance in patients with newly diagnosed multiple myeloma: long-term follow-up of the HOVON-65\/GMMG-HD4 Trial. Blood 2015; 126: 27\u201327.","journal-title":"Blood"},{"key":"BFbcj201723_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3324\/haematol.2013.087585","volume":"99","author":"C Scheid","year":"2014","unstructured":"Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65\/GMMG-HD4 trial. Haematologica 2014; 99: 148\u2013154.","journal-title":"Haematologica"},{"key":"BFbcj201723_CR47","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","volume":"119","author":"K Neben","year":"2012","unstructured":"Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012; 119: 940\u2013948.","journal-title":"Blood"},{"key":"BFbcj201723_CR48","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12: 431\u2013440.","journal-title":"Lancet Oncol"},{"key":"BFbcj201723_CR49","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/annonc\/mdv563","volume":"27","author":"A Lassalle","year":"2016","unstructured":"Lassalle A, Thomare P, Fronteau C, Mahe B, Jube C, Blin N et al. Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study. Ann Oncol 2016; 27: 314\u2013318.","journal-title":"Ann Oncol"},{"key":"BFbcj201723_CR50","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016; 374: 1621\u20131634.","journal-title":"N Engl J Med"},{"key":"BFbcj201723_CR51","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","volume":"17","author":"D Chauhan","year":"2011","unstructured":"Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011; 17: 5311\u20135321.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201723_CR52","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","volume":"70","author":"E Kupperman","year":"2010","unstructured":"Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010; 70: 1970\u20131980.","journal-title":"Cancer Res"},{"key":"BFbcj201723_CR53","doi-asserted-by":"publisher","first-page":"7313","DOI":"10.1158\/1078-0432.CCR-11-0636","volume":"17","author":"EC Lee","year":"2011","unstructured":"Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J et al. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res 2011; 17: 7313\u20137323.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201723_CR54","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","volume":"15","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol 2014; 15: 1503\u20131512.","journal-title":"Lancet Oncol"},{"key":"BFbcj201723_CR55","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","volume":"110","author":"DJ Kuhn","year":"2007","unstructured":"Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110: 3281\u20133290.","journal-title":"Blood"},{"key":"BFbcj201723_CR56","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120: 2817\u20132825.","journal-title":"Blood"},{"key":"BFbcj201723_CR57","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.clml.2012.08.003","volume":"12","author":"S Jagannath","year":"2012","unstructured":"Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012; 12: 310\u2013318.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFbcj201723_CR58","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372: 142\u2013152.","journal-title":"N Engl J Med"},{"key":"BFbcj201723_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3324\/haematol.2015.139352","volume":"101","author":"S Bringhen","year":"2016","unstructured":"Bringhen S, De Paoli L, Larocca A, Ballanti S, Gentilini F, Liberati AM et al. Weekly carfilzomib, cyclophosphamide and dexamethasone (WKCYD) followed by maintenance with weekly carfilzomib (WK) in elderly patients with newly diagnosed multiple myeloma (NDMM). Haematologica 2016; 101: 1\u2013881.","journal-title":"Haematologica"},{"key":"BFbcj201723_CR60","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015; 373: 621\u2013631.","journal-title":"N Engl J Med"},{"key":"BFbcj201723_CR61","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015; 373: 1207\u20131219.","journal-title":"N Engl J Med"},{"key":"BFbcj201723_CR62","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","volume":"387","author":"S Lonial","year":"2016","unstructured":"Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016; 387: 1551\u20131560.","journal-title":"Lancet"},{"key":"BFbcj201723_CR63","first-page":"LBA4","volume":"34","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan AAA, Weisel K, Nooka AK, Masszi T, Beksac M et al. Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. ASCO Meeting Abstr 2016; 34: LBA4.","journal-title":"ASCO Meeting Abstr"},{"key":"BFbcj201723_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3324\/haematol.2015.133629","volume":"101","author":"M Dimopoulos","year":"2016","unstructured":"Dimopoulos M, Oriol A, Nahi N, San Miguel J, Bahlis N, Rabin N et al. An open-label, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRD) versus lenalidomide and dexamethasone (RD) in relapsed or refractory multiple myeloma (RRMM): POLLUX. Haematologica 2016; 101: 1\u2013881.","journal-title":"Haematologica"},{"key":"BFbcj201723_CR65","doi-asserted-by":"publisher","first-page":"11136","DOI":"10.1158\/0008-5472.CAN-05-0599","volume":"65","author":"S Skov","year":"2005","unstructured":"Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N . Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 2005; 65: 11136\u201311145.","journal-title":"Cancer Res"},{"key":"BFbcj201723_CR66","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/nar\/gkj462","volume":"34","author":"M Gialitakis","year":"2006","unstructured":"Gialitakis M, Kretsovali A, Spilianakis C, Kravariti L, Mages J, Hoffmann R et al. Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A. Nucleic Acids Res 2006; 34: 765\u2013772.","journal-title":"Nucleic Acids Res"},{"key":"BFbcj201723_CR67","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1073\/pnas.052702999","volume":"99","author":"F Leoni","year":"2002","unstructured":"Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002; 99: 2995\u20133000.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj201723_CR68","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/10428190701817258","volume":"49","author":"P Richardson","year":"2008","unstructured":"Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008; 49: 502\u2013507.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201723_CR69","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-08-2850","volume":"15","author":"A Badros","year":"2009","unstructured":"Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009; 15: 5250\u20135257.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201723_CR70","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clml.2012.07.007","volume":"12","author":"DM Weber","year":"2012","unstructured":"Weber DM, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L et al. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and\/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012; 12: 319\u2013324.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFbcj201723_CR71","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","volume":"14","author":"M Dimopoulos","year":"2013","unstructured":"Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol 2013; 14: 1129\u20131140.","journal-title":"Lancet Oncol"},{"key":"BFbcj201723_CR72","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1038\/bcj.2014.23","volume":"4","author":"DS Siegel","year":"2014","unstructured":"Siegel DS, Richardson P, Dimopoulos M, Moreau P, Mitsiades C, Weber D et al. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer J 2014; 4: e202.","journal-title":"Blood Cancer J"},{"key":"BFbcj201723_CR73","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/bjh.13527","volume":"171","author":"DW Sborov","year":"2015","unstructured":"Sborov DW, Benson DM, Williams N, Huang Y, Bowers MA, Humphries K et al. Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. Br J Haematol 2015; 171: 74\u201383.","journal-title":"Br J Haematol"},{"key":"BFbcj201723_CR74","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1158\/0008-5472.CAN-05-4186","volume":"66","author":"P Maiso","year":"2006","unstructured":"Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006; 66: 5781\u20135789.","journal-title":"Cancer Res"},{"key":"BFbcj201723_CR75","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1182\/blood-2006-04-016055","volume":"108","author":"L Catley","year":"2006","unstructured":"Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441\u20133449.","journal-title":"Blood"},{"key":"BFbcj201723_CR76","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014; 15: 1195\u20131206.","journal-title":"Lancet Oncol"},{"key":"BFbcj201723_CR77","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2013-01-481325","volume":"122","author":"PG Richardson","year":"2013","unstructured":"Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013; 122: 2331\u20132337.","journal-title":"Blood"},{"key":"BFbcj201723_CR78","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.3324\/haematol.2015.124164","volume":"100","author":"EM Ocio","year":"2015","unstructured":"Ocio EM, Davila J, Caballero JC, Alonso S, de la Calle VG, Garcia-Sanz R et al. Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. Haematologica 2015; 100: e289\u2013e291.","journal-title":"Haematologica"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201723.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201723","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bcj.2017.23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201723.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T17:25:27Z","timestamp":1671729927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,24]]},"references-count":78,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3]]}},"alternative-id":["BFbcj201723"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2017.23","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,24]]},"assertion":[{"value":"20 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MM received lectures\u2019 honoraria and\/or research support from Janssen, Celgene, Amgen, Takeda, Novartis and Bristol-Myers whose products are discussed in this work. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}